Close
Close

Pfizer - Neoplasms

Partner

Not provided

Rare Disease

Neoplasms

Sponsor

Pfizer

Access Program Information

Primary objective of this study is to allow access and evaluate the safety of crizotinib for patients in Japan with advanced NSCLC harboring a translocation or inversion involving the ROS1 oncogene.

Contact

Contact: (1-800-718-1021)

Locations
  • Japan

Free Newsletter